<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01805921</url>
  </required_header>
  <id_info>
    <org_study_id>RSV001</org_study_id>
    <secondary_id>2011-003589-34</secondary_id>
    <nct_id>NCT01805921</nct_id>
  </id_info>
  <brief_title>RSV001 - A New Vaccine to Prevent Severe Viral Chest Infections.</brief_title>
  <official_title>A Phase I Study to Assess Safety and Immunogenicity of a New Respiratory Syncytial Virus (RSV) Vaccine Based on the RSV Viral Proteins F, N and M2-1 Encoded by Simian Adenovirus (PanAd3-RSV) and Modified Vaccinia Virus Ankara (MVA-RSV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ReiThera Srl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ReiThera Srl</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study we are testing a new vaccine against Respiratory Syncytial Virus (RSV).&#xD;
&#xD;
      This virus can cause respiratory infections such as bronchiolitis and pneumonia. It affects&#xD;
      all ages, but especially infants, adults with a suppressed immune system, and the elderly.&#xD;
      RSV only infects humans and occurs in epidemics each winter. It is the single most common&#xD;
      cause of severe respiratory illness in children.&#xD;
&#xD;
      There is no effective anti-viral medication to treat RSV infections. There is a monoclonal&#xD;
      antibody, which can be given to 'at-risk' children given by injection on a monthly basis&#xD;
      during winter to provide short term protection against infection, but it is only partially&#xD;
      effective and prohibitively expensive. Currently, there is no licensed vaccine to prevent RSV&#xD;
      infection and there remains a real need to develop a vaccine as a cost-effective method to&#xD;
      save lives and reduce the cost of disease caused by RSV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are testing two new RSV vaccines, given in different combinations and by different routes&#xD;
      of administration. Each vaccine uses the same RSV proteins to stimulate immune responses.&#xD;
      These proteins are the F (Fusion), N (Nucleocapsid) and M2-1 (Matrix) proteins. The F protein&#xD;
      sits on the surface of the virus and is needed to infect human cells. Antibodies to this&#xD;
      protein are an important mechanism to prevent infection. The N and M2-1 proteins are needed&#xD;
      for viral replication and are targets of immune recognition.&#xD;
&#xD;
      The two vaccines in this study contain all three of these proteins. However, they are&#xD;
      delivered into the body using different 'vectors', which are harmless carrier viruses. In&#xD;
      this study, we have employed two different vectors:a simian adenoviruses (PanAd3) and&#xD;
      Modified Vaccinia virus Ankara (MVA).&#xD;
&#xD;
      We administer these vaccines using a 'prime-boost' strategy, in which one of these vaccines&#xD;
      is used to 'prime' the immune system, which is then 'boosted' 4 or 8 weeks later, depending&#xD;
      on the groups, by administration of an alternative vaccine or the same vaccine given by a&#xD;
      different route.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>52 Weeks</time_frame>
    <description>The recording and assessment of local and systemic adverse events following administration of each vaccine dose;&#xD;
Fever&#xD;
Headache&#xD;
Nausea and/or vomiting&#xD;
Malaise&#xD;
Myalgia&#xD;
Arthralgia&#xD;
Injection site adverse events (for IM administered vaccine); pain or tenderness, induration, redness and swelling&#xD;
Nasal site adverse events (for IN administered vaccine); pain or tenderness, irritation and discharge&#xD;
Blood parameters&#xD;
Any unsolicited symptom(s) not listed above</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>52 weeks</time_frame>
    <description>Immunological assays to study immune responses to each vaccine, including:&#xD;
Serum antibody response to RSV F antigen&#xD;
Serum antibody response capable of RSV neutralization&#xD;
Quantification of circulating vaccine-induced B-cell secreting antibodies (IgA and IgG) against RSV F antigen&#xD;
Quantification of circulating vaccine-induced T-cell responses against RSV antigens F, N and M2-1&#xD;
Any further exploratory immunology to detect vaccine related immune responses</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Respiratory Syncytial Virus Infections</condition>
  <arm_group>
    <arm_group_label>Arm 1. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 1A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.&#xD;
Group 1B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 2A. Low dose prime PanAd3-RSV given by intra-muscular injection (IM) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 4 weeks.&#xD;
Group 2B. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 3A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost MVA-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.&#xD;
Group 3B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost MVA-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4. Prime PanAd3-RSV (IN), boost PanAd3-RSV (IM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 4A. Low dose prime PanAd3-RSV given intra-nasally (IN) - low dose boost PanAd3-RSV given by intra-muscular injection (IM). 2 volunteers, 18-50 years. Interval: 8 weeks.&#xD;
Group 4B. High dose prime PanAd3-RSV given intra-nasally (IN) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 8 volunteers, 18-50 years. Interval: 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5. No vaccine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Group 5. Non-vaccinated control group. 6 volunteers, 60-75 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 6. MVA-RSV (IM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 6. Single high dose MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 7. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 7. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost PanAd3-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 8. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 8. High dose prime PanAd3-RSV given intra-nasally - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 9. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group 9. High dose prime PanAd3-RSV given by intra-muscular injection (IM) - high dose boost MVA-RSV given by intra-muscular injection (IM). 6 volunteers, 60-75 years. Interval: 8 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PanAd3-RSV given intra-nasally (high dose)</intervention_name>
    <description>High dose = 5x10^10 vp</description>
    <arm_group_label>Arm 3. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 4. Prime PanAd3-RSV (IN), boost PanAd3-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 8. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-RSV given by intra-muscular injection (high dose)</intervention_name>
    <description>High dose = 1x10^8 pfu</description>
    <arm_group_label>Arm 1. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 3. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 6. MVA-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 8. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 9. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PanAd3-RSV given by intra-muscular injection (high dose)</intervention_name>
    <description>High dose = 5x10^10 vp</description>
    <arm_group_label>Arm 1. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 2. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 4. Prime PanAd3-RSV (IN), boost PanAd3-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 7. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 9. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PanAd3-RSV given intranasally (low dose)</intervention_name>
    <description>Low dose = 5x10^9 vp</description>
    <arm_group_label>Arm 3. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 4. Prime PanAd3-RSV (IN), boost PanAd3-RSV (IM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MVA-RSV given by intra-muscular injection (low dose)</intervention_name>
    <description>Low dose = 1x10^7 pfu</description>
    <arm_group_label>Arm 1. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 3. Prime PanAd3-RSV (IN), boost MVA-RSV (IM)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PanAd3-RSV given by intra-muscular injection (low dose)</intervention_name>
    <description>Low dose = 5x10^9 vp</description>
    <arm_group_label>Arm 1. Prime PanAd3-RSV (IM), boost MVA-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 2. Prime PanAd3-RSV (IM), boost PanAd3-RSV (IM)</arm_group_label>
    <arm_group_label>Arm 4. Prime PanAd3-RSV (IN), boost PanAd3-RSV (IM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Participants must satisfy all of the following criteria to be considered eligible for the&#xD;
        study:&#xD;
&#xD;
          -  Willing and able to give informed consent for participation in the study&#xD;
&#xD;
          -  Aged between 18 and 50 years (Groups 1-4) or aged 60-75 years (Groups 5-9)&#xD;
&#xD;
          -  In good health as determined by&#xD;
&#xD;
               -  Medical history&#xD;
&#xD;
               -  Physical examination&#xD;
&#xD;
               -  Clinical judgment of the investigators&#xD;
&#xD;
          -  Willing to use effective contraception&#xD;
&#xD;
               -  Females: The oral contraceptive pill, contraceptive implant or barrier methods&#xD;
                  from one month prior and for the duration of the study (Groups 1-4 only)&#xD;
&#xD;
               -  Males: Barrier contraception from V1 until 3 months after the last vaccination&#xD;
&#xD;
          -  Able to attend the scheduled visits and to comply with all study procedures&#xD;
&#xD;
          -  Willing to allow his or her General Practitioner and/or Consultant, if appropriate, to&#xD;
             be notified of participation in the study&#xD;
&#xD;
          -  Confirmation from GP that they are aware of the inclusion and exclusion criteria and&#xD;
             are satisfied from their knowledge of the volunteer that they are suitable to enroll&#xD;
&#xD;
          -  Willing to provide their National Insurance/Passport number for the purpose of TOPS&#xD;
             registration&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        The participant may not enter the study if any of the following apply:&#xD;
&#xD;
          -  History of significant organ/system disease that could interfere with trial conduct or&#xD;
             completion. This includes any history of significant disease in the following;&#xD;
&#xD;
               -  Cardiovascular disease including congenital heart disease, previous myocardial&#xD;
                  infarction, valvular heart disease (or history of rheumatic fever), previous&#xD;
                  bacterial endocarditis, history of cardiac surgery (including pacemaker&#xD;
                  insertion), personal or family history of cardiomyopathy or sudden adult death&#xD;
&#xD;
               -  Respiratory disease such as asthma (excluding childhood asthma not treated in&#xD;
                  adulthood) and chronic obstructive pulmonary disease&#xD;
&#xD;
               -  Endocrine disorders such as diabetes mellitus and Addison's disease&#xD;
&#xD;
               -  Significant renal or bladder disease, including history of renal calculi&#xD;
&#xD;
               -  Biliary tract disease&#xD;
&#xD;
               -  Gastro-intestinal disease such as inflammatory bowel disease, abdominal surgery&#xD;
                  within the last two years, coeliac disease and liver disease&#xD;
&#xD;
               -  Neurological disease such as seizures and myasthenia gravis&#xD;
&#xD;
               -  Metabolic disease such as glucose-6-phosphate dehydrogenase deficiency&#xD;
&#xD;
               -  Psychiatric illness requiring hospitalization or depression whose severity is&#xD;
                  deemed clinical significant by the Chief Investigator, Consultant or GP&#xD;
&#xD;
               -  Non-benign cancer, including squamous cell carcinoma, basal cell carcinoma of the&#xD;
                  skin and cervical carcinoma in situ&#xD;
&#xD;
               -  Clinically significant contact dermatitis&#xD;
&#xD;
          -  Have any known or suspected impairment or alteration of immune function, resulting&#xD;
             from, for example:&#xD;
&#xD;
               -  Congenital or acquired immunodeficiency&#xD;
&#xD;
               -  Human Immunodeficiency Virus infection or symptoms/signs suggestive of an&#xD;
                  HIV-associated condition&#xD;
&#xD;
               -  Autoimmune disease&#xD;
&#xD;
               -  Receipt of immunosuppressive therapy such as anti-cancer chemotherapy or&#xD;
                  radiation therapy within the preceding 12 months or long-term systemic&#xD;
                  corticosteroid therapy&#xD;
&#xD;
               -  Receipt of immunoglobulin or any blood product transfusion within 3 months of&#xD;
                  study start&#xD;
&#xD;
          -  A vaccination history indicative of;&#xD;
&#xD;
               -  Planning to receive any vaccine other than the study vaccine within 4 weeks&#xD;
                  following vaccination&#xD;
&#xD;
               -  A history of anaphylaxis reaction to a vaccine&#xD;
&#xD;
               -  History of allergic disease or reactions likely to be exacerbated by any&#xD;
                  component of the vaccine, e.g. Kathon&#xD;
&#xD;
               -  Previously having received a recombinant simian or human adenoviral vaccine&#xD;
&#xD;
               -  Previously having received a recombinant MVA vaccine&#xD;
&#xD;
          -  Detection of any of the following at screening&#xD;
&#xD;
               -  IgA deficiency&#xD;
&#xD;
               -  Anti-HIV antibody&#xD;
&#xD;
               -  Hepatitis B surface antigen&#xD;
&#xD;
               -  Anti-HCV antibody&#xD;
&#xD;
               -  Any other significant abnormalities on screening investigations at the discretion&#xD;
                  of an Investigator&#xD;
&#xD;
          -  Known or suspected drug and/or alcohol misuse (alcohol misuse defined as an intake&#xD;
             exceeding 42 units per week)&#xD;
&#xD;
          -  Nasal septal pathology including&#xD;
&#xD;
               -  Congenital deformities such as an abnormal septum or polyps&#xD;
&#xD;
               -  Previous cauterization, rhinoplasty or surgery of any kind&#xD;
&#xD;
               -  Recurrent epistaxis&#xD;
&#xD;
          -  Scheduled procedures requiring general anaesthesia during the study&#xD;
&#xD;
          -  Participation in another research study involving an investigational product in the&#xD;
             past 12 weeks, or are planning to do so within the 20 weeks of this study&#xD;
&#xD;
          -  Inability, in the opinion of the Investigator, to comply with all study requirements&#xD;
&#xD;
          -  Female participants who are pregnant, lactating or planning pregnancy during the&#xD;
             course of the study&#xD;
&#xD;
          -  Has donated blood within 4 months before starting the trial, or is intending to donate&#xD;
             blood during the trial and up to 12 weeks after completing the study&#xD;
&#xD;
          -  Any other significant disease or disorder which, in the opinion of the Investigator,&#xD;
             may&#xD;
&#xD;
               -  Put the participants at risk because of participation in the study&#xD;
&#xD;
               -  Influence the result of the study&#xD;
&#xD;
               -  Impair the participant's ability to participate in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Pollard, FRCPCH PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Oxford. Department of Paediatrics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Clinical Vaccinology &amp; Tropical Medicine (CCVTM)</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 7LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ovg.ox.ac.uk/recruiting-studies</url>
    <description>More study information will be available from the Oxford Vaccine Group website once recruitment opens</description>
  </link>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>March 5, 2013</study_first_submitted>
  <study_first_submitted_qc>March 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2013</study_first_posted>
  <last_update_submitted>April 24, 2016</last_update_submitted>
  <last_update_submitted_qc>April 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Respiratory Syncytial Virus</keyword>
  <keyword>RSV</keyword>
  <keyword>Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>March 18, 2019</submitted>
    <returned>June 18, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

